NYSE:VOR Vor Biopharma (VOR) News Today $2.12 0.00 (0.00%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$2.08▼$2.2450-Day Range$2.10▼$3.1752-Week Range$2.03▼$7.57Volume110,989 shsAverage Volume76,146 shsMarket Capitalization$143.18 millionP/E RatioN/ADividend YieldN/APrice Target$15.19 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVor Biopharma Inc. (NYSE:VOR) Receives Average Rating of "Buy" from Analystsamericanbankingnews.com - September 30 at 2:22 AMBaker BROS. Advisors LP Trims Stock Position in Vor Biopharma Inc. (NYSE:VOR)marketbeat.com - September 12 at 5:41 AMJonesTrading Initiates a Buy Rating on Prime Medicine, Inc. (PRME)markets.businessinsider.com - September 5 at 8:38 PMVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by Brokeragesmarketbeat.com - September 5 at 2:16 AMVor Biopharma (NASDAQ: VOR)fool.com - August 16 at 9:02 PMJMP Securities Reiterates Vor Biopharma (VOR) Market Outperform Recommendationmsn.com - August 14 at 4:20 PMThe Latest Analyst Ratings for Vor Biopharmamarkets.businessinsider.com - August 14 at 4:20 PMRA Capital Management, L.P. Increases Stake in Vor Biopharma Inc.gurufocus.com - August 12 at 5:04 AMBarclays Keeps Their Buy Rating on Vor Biopharma (VOR)markets.businessinsider.com - August 12 at 12:41 AMH.C. Wainwright Reaffirms Their Buy Rating on Vor Biopharma (VOR)markets.businessinsider.com - August 11 at 7:39 PMWedbush Maintains Vor Biopharma (VOR) Outperform Recommendationmsn.com - August 11 at 7:39 PMVor Biopharma (NYSE:VOR) Price Target Lowered to $15.00 at Stifel Nicolausmarketbeat.com - August 11 at 1:45 PMVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - August 11 at 10:49 AMVor Bio Reports Second Quarter 2023 Financial Results and Provides Company Updatefinance.yahoo.com - August 11 at 3:14 AMSolu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targetstechnews.tmcnet.com - August 1 at 8:37 PMVeeva Systems: Veeva Pulse Uncovers Field Medical Engagement Drives 1.5x Increase in Treatment Adoptionfinanznachrichten.de - July 26 at 4:42 PMVeeva Pulse zeigt, dass Interaktionen mit dem medizinischen Außendienst die Therapieakzeptanz um das 1,5-fache steigernde.finance.yahoo.com - July 26 at 4:42 PMRobert W. Baird Sticks to Its Buy Rating for Bluebird Bio (BLUE)markets.businessinsider.com - June 22 at 7:23 AMRobert W. Baird Keeps Their Buy Rating on Vor Biopharma (VOR)markets.businessinsider.com - June 22 at 7:23 AMPOINT Biopharma Global (PNT) Gets a Buy from JonesTradingmarkets.businessinsider.com - June 21 at 9:20 AMVor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - June 19 at 4:34 AMWhat 11 Analyst Ratings Have To Say About Vor Biopharmamarkets.businessinsider.com - June 12 at 6:59 PMVor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patientsmarkets.businessinsider.com - June 9 at 2:50 PMVor Biopharma: Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platformfinanznachrichten.de - June 9 at 9:50 AMSuccessful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platformfinance.yahoo.com - June 9 at 9:50 AMVor Bio to Participate in the Goldman Sachs Healthcare Conferencefinance.yahoo.com - June 5 at 10:50 AMVOR - Vor Biopharma Inc.uk.finance.yahoo.com - May 25 at 8:48 AMJonesTrading Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendationmsn.com - May 16 at 8:24 PMOppenheimer Reiterates Vor Biopharma (VOR) Outperform Recommendationmsn.com - May 16 at 3:23 PMHC Wainwright & Co. Reiterates Vor Biopharma (VOR) Buy Recommendationmsn.com - May 16 at 3:23 PMVor Biopharma (VOR) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - May 16 at 10:18 AMOppenheimer Sticks to Their Buy Rating for Vor Biopharma (VOR)markets.businessinsider.com - May 15 at 7:24 PM8 Analysts Have This to Say About Vor Biopharmamsn.com - May 15 at 7:24 PMWedbush Weighs in on Vor Biopharma Inc.'s FY2027 Earnings (NYSE:VOR)marketbeat.com - May 15 at 4:38 AMWedbush Reaffirms Their Buy Rating on Vor Biopharma (VOR)markets.businessinsider.com - May 12 at 5:56 PMWedbush Reiterates Vor Biopharma (VOR) Outperform Recommendationmsn.com - May 12 at 12:55 PMJMP Securities Remains a Buy on Vor Biopharma (VOR)markets.businessinsider.com - May 12 at 2:54 AMVor Biopharma: EPS übertrifft Schätzungen um 0,11$ - Umsatz wie erwartetde.investing.com - May 11 at 9:53 PMVor Biopharma GAAP EPS of -$0.43 misses by $0.05msn.com - May 11 at 9:53 PMVor Biopharma: Q1 Earnings Insightsmsn.com - May 11 at 9:53 PMVor Bio Reports First Quarter 2023 Financial Results and Provides Company Updatefinance.yahoo.com - May 11 at 4:53 PMVor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Buy" by Analystsmarketbeat.com - April 30 at 4:14 AMVor Biopharma Inc. (NYSE:VOR) Given Average Rating of "Moderate Buy" by Brokeragesmarketbeat.com - April 5 at 4:33 AMVor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cellsseekingalpha.com - March 29 at 7:11 PMHow Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%finance.yahoo.com - March 28 at 12:21 PMWedbush Weighs in on Vor Biopharma Inc.'s Q1 2024 Earnings (NYSE:VOR)marketbeat.com - March 27 at 2:38 AMBarclays Cuts Vor Biopharma (NYSE:VOR) Price Target to $10.00marketbeat.com - March 26 at 7:28 AMVor Biopharma Inc. (VOR) stock historical prices & data – Yahoo Financeuk.finance.yahoo.com - March 25 at 11:38 PMWhere Vor Biopharma Stands With Analystsmarkets.businessinsider.com - March 24 at 2:59 PMTruist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Knowmsn.com - March 24 at 2:59 PM Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address VOR Media Mentions By Week VOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.000.68▲Average Medical News Sentiment VOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼11▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RANI News Today ABSI News Today ONCY News Today HYPR News Today ASRT News Today SGMO News Today OPTN News Today SGHT News Today GRPH News Today ALT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NYSE:VOR) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.